This study demonstrates a promising way to regenerate bone and paves the way for exploring the use of CERAMENTT as a carrier for delivery of bone active proteins and drugs that together with native muscle cells can modulate and enhance bone healing in a variety of clinical applications.” said Professor Magnus Tägil, of the Department of Orthopedics, Clinical Sciences, Lund University.
CERAMENTT is an injectable, resorbable bone graft substitute designed to fill bone gaps and voids and to augment hardware and bone fractures during surgical procedures. CERAMENTT has been shown to remodel into healthy native bone within 6 to 12 months and has been used in more than 10,000 procedures worldwide. CERAMENTT’G and CERAMENTT’V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of bone infection.
“We are grateful to the researchers who participated in this study and to EFORT for their recognition of this important work,” said Lloyd Diamond, CEO of BONESUPPORT. “CERAMENTT continues to gain traction in the synthetic bone market and we see a three step pattern that is driving procedure volume; the breadth of clinical data to support our claims; the easy mixing and handling characteristics of CERAMENTT; and most importantly, post-operative x-rays which clearly show complete bone remodeled.”
Each year, the EFORT Award Committee reviews thousands of high-quality papers and poster submissions and selects the top submissions for a series of awards.
BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedics, and trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENTT is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENTT’G and CERAMENTT’V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections). CERAMENT’s unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENTT’G and CERAMENTT’V are not available in the United States.
CERAMENTT is a fully developed product platform that is commercially available in the U.S., Europe, SE Asia and the Middle East. CERAMENTT is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and more than 10,000 patients have been treated with CERAMENT. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit www.bonesupport.com.